Calgary, Alberta — November 20, 2025 — Hemostemix Inc. announced that Dr. William R. Shankle, MS, MD, FACP, a leading neurologist in cognitive disorders, will oversee the Phase 1 clinical trial of ACP-01, the company’s autologous angiogenic cell-therapy candidate being evaluated as a potential treatment for vascular dementia (VaD). With ACP-01 already used in compassionate and clinical settings for ischemic diseases, this marks a significant expansion into neurovascular cognitive disorders.
Science Significance
The advancement of ACP-01 into vascular-dementia research represents a major scientific milestone in regenerative medicine and cell-based neurovascular repair. ACP-01 is composed of angiogenic cell precursors derived from a patient’s own blood and is designed to support angiogenesis, microvascular repair, and tissue perfusion—all of which are central to addressing the vascular deficiencies that drive VaD. Dr. Shankle’s decades of work in cognitive neurology, early diagnosis of dementia and neurovascular pathology lend scientific rigor to this trial, supporting the hypothesis that restoring microvascular health may improve cognitive resilience in patients with vascular-related cognitive decline. The trial will also deepen understanding of how autologous stem-cell platforms may benefit neurologic conditions traditionally managed only with symptomatic therapies.
Regulatory Significance
Advertisement
In regulatory terms, the submission and revision of the Phase 1 trial protocol to an Institutional Review Board (IRB) marks a critical step in the formal governance process of advancing ACP-01 toward human testing in vascular dementia. The IRB’s initial comments have been addressed, and Hemostemix will resubmit the revised protocol for final approval, demonstrating compliance with GCP (Good Clinical Practice) standards and ethical oversight. Importantly, ACP-01 remains an investigational therapy not approved by the FDA or Health Canada for VaD, but this trial positions Hemostemix to generate foundational safety, feasibility, and preliminary-efficacy evidence essential for subsequent regulatory pathways, including potential IND submissions and multi-site clinical expansions.
Business Significance
The move into vascular-dementia therapeutics significantly enhances the commercial scope of Hemostemix’s ACP-01 autologous platform, historically used to address chronic limb threatening ischemia, peripheral arterial disease, dilated cardiomyopathy, ischemic cardiomyopathy, angina, and heart failure. By appointing Dr. Shankle—an internationally recognized clinician with extensive academic affiliations—the company strengthens its market credibility and clinical leadership. The ability to target cognitive disorders driven by vascular injury positions Hemostemix for growth in a high-demand therapeutic area with limited effective treatments. This development may also align with broader commercialization efforts, including compassionate-use pathways such as those permitted under emerging legislation in certain jurisdictions.
Patients’ Significance
Patients affected by vascular dementia face progressive memory decline, impaired cognitive processing and diminished quality of life, with no approved disease-modifying treatments currently available. Hemostemix’s initiative offers a potential breakthrough for patients experiencing VaD driven by chronic cerebrovascular insufficiency. Dr. Shankle is actively pre-screening up to 30 patients from a database of approximately 500 individuals with cognitive impairment, ensuring that the trial population reflects those most likely to benefit. If ACP-01 delivers meaningful improvements in cognition or stabilizes decline, it may offer patients a highly personalized, autologous option grounded in vascular repair rather than symptomatic management.
Policy Significance
From a policy perspective, the ACP-01 program contributes to national and global priorities aimed at combating dementia-related disease burdens, which consume substantial healthcare resources. The emphasis on autologous cell therapy, ethical review, and regulatory compliance reflects evolving policy frameworks surrounding regenerative medicine. Advancing a cell-therapy into a cognition-related indication highlights the increasing need for updated reimbursement models, long-term patient-monitoring standards and cross-jurisdictional regulatory harmonization. Hemostemix’s ongoing commitment to transparency, including forward-looking risk disclosures, aligns with emerging expectations in public-policy environments that prioritize patient safety and innovation in neurodegenerative disease management.
Hemostemix’s decision to appoint Dr. William R. Shankle to lead the Phase 1 clinical trial of ACP-01 for vascular dementia marks a strategically significant moment for the company and for the future of regenerative cognitive therapeutics. Anchored in robust clinical experience, scientific credibility and regulatory diligence, this effort positions ACP-01 to become a pioneering autologous stem-cell approach targeting the vascular drivers of cognitive decline. As Hemostemix advances its IRB-approved protocol and prepares for enrollment, the project demonstrates a clear commitment to addressing one of the most pressing unmet needs in neurology and age-related healthcare.
Source: Hemostemix Inc. press release
